DDInter1643 DDInter1435
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Sarilumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Sarilumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Sarilumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Sarilumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Sarilumab may lead to a major life threatening interaction when taken with Cladribine
Sarilumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live